Latest News - Dementia & Cognitive Disorders

Thursday, January 17, 2019

First Patient Enrolled in Phase 3 Trial of Low-Dose Formulation of Levetiracetam for Mild Cognitive Impairment

A first patient has been enrolled in a phase 3 clinical trial of a proprietary low-dose formulation of the antiepileptic drug levetiracetam (AGB101; AgeneBio, Baltimore,MD) for the treatment of amnest…

Read the full story

Wednesday, January 09, 2019

Breakthrough Device Designation Granted to Brain-Monitoring Technology

The Food and Drug Administration has granted breakthrough device designation to a brain health monitoring technology (Neurametrix; San Francisco, CA). The approved use is monitoring Parkinson’s …

Read the full story

Thursday, January 03, 2019

American Academy of Neurology Call for Uniformity in Brain Death Standards

Noting that only 1 state, Nevada, has adopted legislation requiring use of medically accepted guidelines for determining brain death, the American Academy of Neurology (AAN) is calling for action on t…

Read the full story

Wednesday, December 26, 2018

Study Defines Risk Factors for REM Sleep Behavior Disorder

A study published in Neurology online found that taking antidepressants for depression or having anxiety or post-traumatic stress disorder (PTSD) are correlated with the disruptive and somet…

Read the full story

Wednesday, December 12, 2018

Increased Dementia Risk for Female Veterans Who Experienced Brain Injuries

In a study published in Neurology, it was found that women who served in the military and have traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), or depression are more likely ev…

Read the full story

Monday, December 10, 2018

Tau Aggregation Inhibitor Receives Orphan Drug Status for Treatment of Frontotemporal Dementia

Orphan drug designation has been granted to a tau aggregation inhibitor leucomethylthioninium (LMTX) (TauRx, Aberdeen, Scotland) being studied in phase 3 clinical trials for the treatment of frontotem…

Read the full story

Monday, December 10, 2018

New Drug Candidate for Alzheimer’s Disease to Enter Phase 1 Trials

The investigational drug candidate E2814, designed to slow the progression of Alzheimer’s disease, will enter phase 1 clinical trials in early 2019. A monoclonal antibody, E2814 targets tau &…

Read the full story

Wednesday, November 28, 2018

Biases in Dementia Screening Tools

Brief cognitive tests are useful screening tools for dementia in the primary care setting; however, a study published in the journal Neurology Clinical Practice shows that 3 of the most comm…

Read the full story

Wednesday, November 21, 2018

Consuming Orange Juice, Leafy Greens, and Berries Is Related to Less Memory Loss in Men

A study published in Neurology states that eating leafy greens, dark orange and red vegetables, and berry fruits, and drinking orange juice is related to less memory loss in men.  Th…

Read the full story

Friday, November 16, 2018

New Campaign Urges Women to Take The Lead on Brain Health

A new campaign, Be Brain Powerful (, has been launched to encourage women to talk about brain health and take steps to preserve cognitive function has been launched. This $2 m…

Read the full story

Wednesday, November 14, 2018

Study Confirms Benefits of Laser Interstitial Thermal Therapy

A prospective, multi-center clinical study of 42 patients with brain lesions that recurred after stereotactic radiosurgery (SRS) for metastatic brain tumors showed positive outcomes for lase…

Read the full story

Wednesday, November 07, 2018

Another Beta-Secretase 1 (BACE) Inhibitor Phase 3 Trial Stopped

A trial of investigational drugs LY3202626 and LY3002813 (also known as N3pG mAB) (BACE IV; Eli Lilly, Indianapolis, IN) in combination for patients with Alzheimer’s disease (AD) has been termin…

Read the full story

Tuesday, October 30, 2018

Positive Top-Line Results Announced from Phase 2 Study of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder

Pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA), already approved for treatment of patients with Parkinson’s disease (PD) psychosis is also being studied as a potential adjunctive…

Read the full story

Monday, October 29, 2018

Evidence Growing That Eyes May Be A Window to Alzheimer’s Diagnosis

Results presented at the 122ndAnnual Meeting of the American Academy of Ophthalmology suggest that optical coherence tomography (OCT) and OCT-angiography (OCTA) may be diagnostic for patients with pre…

Read the full story

Wednesday, October 24, 2018

Correlation of Higher Cortisol Levels, Cognitive Deficits, and Lower Brain Volume Varies by Sex

In a study published in today’s issue of Neurology, data from participants in the Framingham Heart study (generation 3) identified a correlation among high blood cortisol levels (> 15.8 …

Read the full story
Load More